Exchange: NASDAQ·Updated 06:20 AM EDT
ARVN logo

ARVNArvinas Inc

$8.11
$0.09
(1.10%)
Pre-Market
Prev Close $8.20
EarningsAug 5
Mkt Cap$536.17M
Vol18.00
News
all
press releases
uniQure (QURE) Soars 78.4%: Is Further Upside Left in the Stock?
uniQure (QURE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Zacks
News Placeholder
More News
News Placeholder
Twist Bioscience (TWST) Surges 9.3%: Is This an Indication of Further Gains?
Twist Bioscience (TWST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks
News Placeholder
Full Transcript: Arvinas Q1 2026 Earnings Call
read more...
Benzinga
News Placeholder
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer
Rigel Pharmaceuticals stock jumps after signing a VEPPANU licensing deal with Arvinas and Pfizer following recent FDA approval.read more...
Benzinga
News Placeholder
RIGL Stock Jumps 15%, Short Interest Surges To Record High – Why Is Retail Eyeing A Further 40% Upside?
Rigel Pharmaceuticals signed a global licensing deal with Arvinas and Pfizer for an advanced breast cancer treatment.
Stocktwits
News Placeholder
Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates
Arvinas (ARVN) delivered earnings and revenue surprises of +5.01% and -0.74%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Rigel Pharma Signs Licensing Agreement With Arvinas And Pfizer For Veppanu
(RTTNews) - Rigel Pharmaceuticals, Inc. (RIGL) on Tuesday said it has entered into a global license agreement with Arvinas, Inc. (ARVN) and Pfizer Inc. (PFE) to develop, manufacture and commercialize beast cancer treatment Veppanu...
Nasdaq News: Markets
News Placeholder
Septerna, Inc. (SEPN) Reports Q1 Loss, Tops Revenue Estimates
Septerna, Inc. (SEPN) delivered earnings and revenue surprises of +63.04% and +32.93%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Codexis (CDXS) Reports Q1 Loss, Beats Revenue Estimates
Codexis (CDXS) delivered earnings and revenue surprises of +9.09% and +1.82%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Earnings Preview: ProQR (PRQR) Q1 Earnings Expected to Decline
ProQR (PRQR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
<
1
2
...
>

Advertisement|Remove ads.